サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1605803

乳がんリキッドバイオプシー市場、規模、シェア、動向、産業分析レポート：循環バイオマーカー別、用途別、地域別 - 市場予測 2025年～2034年

Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast (2025-2034)

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
乳がんリキッドバイオプシー市場、規模、シェア、動向、産業分析レポート：循環バイオマーカー別、用途別、地域別 - 市場予測 2025年～2034年
出版日: 2024年11月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、乳がんリキッドバイオプシーの世界市場規模は2034年までに27億3,102万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

乳がんリキッドバイオプシー市場は、世界の乳がん有病率の増加と非侵襲的診断ツールに対する需要の高まりにより、大きな成長を遂げています。リキッドバイオプシーは、血液サンプルから循環腫瘍DNA（ctDNA）と循環腫瘍細胞（CTC）を分析します。従来の組織生検に比べ、患者の不快感を軽減し、治療効果をリアルタイムでモニターできるなど、いくつかの利点があります。分子生物学とゲノミクスの進歩によりリキッドバイオプシー検査は改善され、乳がんの早期発見とより正確な治療が可能になり、市場の成長をさらに後押ししています。

がん早期発見の利点に関するヘルスケア専門家や患者の意識の高まりが、リキッド生検ソリューションの需要を促進しています。がん検診を推進する政府の取り組みや研究助成金も、市場の成長を促進する上で重要な役割を果たしています。さらに、個別化医療へのシフトにより標的治療が重視されるようになり、リキッドバイオプシーは患者固有の遺伝子プロファイルに基づいて個々の患者に合わせた治療を行うための不可欠なツールとなっています。

大手バイオテクノロジー企業や製薬企業の存在と、活発な研究開発活動は、この分野の技術革新をさらに刺激しています。ヘルスケアの状況が進化し、リキッドバイオプシー技術を採用する医療機関が増えるにつれて、リキッドバイオプシーは乳がんの診断と管理を改善し、患者の転帰を向上させる。上記のこれらすべての要因が乳がんリキッドバイオプシー市場の成長を促進します。

乳がんリキッドバイオプシー市場レポートハイライト

循環バイオマーカーに基づくと、2024年には、循環無細胞DNA（cfDNA）セグメントは、その感度の向上により乳がんリキッドバイオプシー市場で最大の売上シェアを占めました。

早期がん診断の重要性に対する認識が高まっていることから、早期発見／スクリーニング分野は、予測期間中に最も高いCAGRを記録すると予想されます。

2024年には、北米が乳がんリキッドバイオプシー市場で最大のシェアを占めたが、これは同地域全体で革新的診断技術の採用率が高いためです。

アジア太平洋市場は、この地域全体で乳がんの有病率が増加していることから、予測期間中に最も高いCAGRを記録すると予想されます。

世界の主な市場参入企業は、Biocept, Inc.、Epic Sciences, Inc.、F. Hoffmann-La Roche Ltd.、Fluxion Biosciences, Inc.、Myriad Genetics, Inc.、NeoGenomics Laboratories、QIAGEN、Sysmex Corporation、The Menarini Group、Thermo Fisher Scientific, Inc.などです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の乳がんリキッドバイオプシー市場の洞察

  • 市場スナップショット
  • 乳がんリキッドバイオプシー市場力学
    • 促進要因と機会
      • 技術の進歩が市場の成長を牽引
      • 乳がん罹患率の上昇が市場の成長を牽引
    • 抑制要因と課題
      • 高い開発コスト
  • PESTEL分析
  • 乳がんリキッドバイオプシー市場のアプリケーション動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の乳がんリキッドバイオプシー市場：循環バイオマーカー別

  • 主な調査結果
  • イントロダクション
  • 循環腫瘍細胞（CTC）
  • 循環遊離DNA（cfDNA）
  • 細胞外小胞（EV）
  • その他の循環バイオマーカー

第6章 世界の乳がんリキッドバイオプシー市場：用途別

  • 主な調査結果
  • イントロダクション
  • 早期発見・スクリーニング
  • 診断
  • 監視

第7章 世界の乳がんリキッドバイオプシー市場：地域別

  • 主な調査結果
  • イントロダクション
    • 乳がんリキッドバイオプシー市場評価：地域別、2020年～2034年
  • 北米
    • 北米：循環バイオマーカー別、2020年～2034年
    • 北米：用途別、2020年～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：循環バイオマーカー別、2020年～2034年
    • 欧州：用途別、2020年～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：循環バイオマーカー別、2020年～2034年
    • アジア太平洋地域：用途別、2020年～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：循環バイオマーカー別、2020年～2034年
    • 中東・アフリカ：用途別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：循環バイオマーカー別、2020年～2034年
    • ラテンアメリカ：用途別、2020年～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • The Menarini Group
  • NeoGenomics Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Biocept, Inc.
  • Sysmex Corporation
  • Fluxion Biosciences, Inc.
  • Epic Sciences, Inc.
図表

List of Tables:

  • Table 1 Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 2 Global Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 3 North America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 4 North America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 5 U.S.: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 6 U.S.: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 7 Canada: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 8 Canada: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 9 Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 10 Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 11 UK: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 12 UK: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 13 France: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 14 France: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 15 Germany: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 16 Germany: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 17 Italy: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 18 Italy: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 19 Spain: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 20 Spain: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 21 Netherlands: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 22 Netherlands: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 23 Russia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 24 Russia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 25 Rest of Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 26 Rest of Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 27 Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 28 Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 29 China: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 30 China: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 31 India: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 32 India: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 33 Malaysia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 34 Malaysia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 35 Japan: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 36 Japan: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 37 Indonesia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 38 Indonesia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 39 South Korea: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 40 South Korea: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 41 Australia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 42 Australia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 43 Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 44 Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 45 Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 46 Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 47 Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 48 Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 49 UAE: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 50 UAE: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 51 Israel: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 52 Israel: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 53 South Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 54 South Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 55 Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 56 Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 57 Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 58 Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 59 Mexico: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 60 Mexico: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 61 Brazil: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 62 Brazil: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 63 Argentina: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 64 Argentina: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 65 Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 66 Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • List of Figures:
  • Figure 1. Global Breast Cancer Liquid Biopsy Market, 2020-2034 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Circulating Biomarkers
  • Figure 7. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2024 & 2034 (USD Million)
  • Figure 8. Market by Application
  • Figure 9. Global Breast Cancer Liquid Biopsy Market, by Application, 2024 & 2034 (USD Million)
目次
Product Code: PM5160

The global breast cancer liquid biopsy market size is expected to reach USD 2,731.02 million by 2034, according to a new study by Polaris Market Research. The report "Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report - By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The breast cancer liquid biopsy market is experiencing significant growth due to the increasing prevalence of breast cancer globally and the rising demand for noninvasive diagnostic tools. Liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples. It offers several advantages over traditional tissue biopsies, including reduced patient discomfort and the ability to monitor treatment response in real time. Advancements in molecular biology and genomics have improved liquid biopsy tests, enabling earlier detection and more precise treatment of breast cancer, further boosting market growth.

The rising awareness among healthcare professionals and patients regarding the benefits of early cancer detection is driving demand for liquid biopsy solutions. Government initiatives promoting cancer screening and research funding also play a crucial role in fostering market growth. In addition, the shift toward personalized medicine is leading to a greater emphasis on targeted therapies, making liquid biopsies an essential tool for tailoring treatments to individual patients based on their unique genetic profiles.

The presence of major biotechnology and pharmaceutical companies, coupled with robust research and development activities, is further stimulating innovation in this sector. As the healthcare landscape evolves and more providers adopt liquid biopsy technology, it improves breast cancer diagnosis and management while enhancing patient outcomes. All these factors mentioned above drive the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.

The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.

In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.

The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.

A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the breast cancer liquid biopsy market report on the basis of circulating biomarkers, application, and region:

By Circulating Biomarkers Outlook (Revenue - USD Million, 2020-2034)

  • Circulating Tumor Cells (CTCs)
  • Circulating Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers

By Application Outlook (Revenue - USD Million, 2020-2034)

  • Early Detection/Screening
  • Diagnosis
  • Treatment Selection
  • Monitoring

By Regional Outlook (Revenue - USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Breast Cancer Liquid Biopsy Market Insights

  • 4.1. Breast Cancer Liquid Biopsy Market - Market Snapshot
  • 4.2. Breast Cancer Liquid Biopsy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Technological Advancements are Driving the Market Growth
      • 4.2.1.2. Rising Prevalence of Breast Cancer are Driving the Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Development Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Breast Cancer Liquid Biopsy Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • 5.3. Circulating Tumor Cells (CTCs)
    • 5.3.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), by Region, 2020-2034 (USD Million)
  • 5.4. Circulating Cell-free DNA (cfDNA)
    • 5.4.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Cell-free DNA (cfDNA), by Region, 2020-2034 (USD Million)
  • 5.5. Extracellular Vesicles (EVs)
    • 5.5.1. Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), by Region, 2020-2034 (USD Million)
  • 5.6. Other Circulating Biomarkers
    • 5.6.1. Global Breast Cancer Liquid Biopsy Market, by Other Circulating Biomarkers, by Region, 2020-2034 (USD Million)

6. Global Breast Cancer Liquid Biopsy Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 6.3. Early Detection/Screening
    • 6.3.1. Global Breast Cancer Liquid Biopsy Market, by Early Detection/Screening, by Region, 2020-2034 (USD Million)
  • 6.4. Diagnosis
    • 6.4.1. Global Breast Cancer Liquid Biopsy Market, by Diagnosis, by Region, 2020-2034 (USD Million)
  • 6.5. Monitoring
    • 6.5.1. Global Breast Cancer Liquid Biopsy Market, by Monitoring, by Region, 2020-2034 (USD Million)

7. Global Breast Cancer Liquid Biopsy Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Breast Cancer Liquid Biopsy Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Breast Cancer Liquid Biopsy Market - North America
    • 7.3.1. North America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.3.2. North America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.3.3. Breast Cancer Liquid Biopsy Market - U.S.
      • 7.3.3.1. U.S.: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.3.3.2. U.S.: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.3.4. Breast Cancer Liquid Biopsy Market - Canada
      • 7.3.4.1. Canada: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.4. Breast Cancer Liquid Biopsy Market - Europe
    • 7.4.1. Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.4.2. Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.3. Breast Cancer Liquid Biopsy Market - UK
      • 7.4.3.1. UK: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.4. Breast Cancer Liquid Biopsy Market - France
      • 7.4.4.1. France: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.4.2. France: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.5. Breast Cancer Liquid Biopsy Market - Germany
      • 7.4.5.1. Germany: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.6. Breast Cancer Liquid Biopsy Market - Italy
      • 7.4.6.1. Italy: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.7. Breast Cancer Liquid Biopsy Market - Spain
      • 7.4.7.1. Spain: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.8. Breast Cancer Liquid Biopsy Market - Netherlands
      • 7.4.8.1. Netherlands: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.9. Breast Cancer Liquid Biopsy Market - Russia
      • 7.4.9.1. Russia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.10. Breast Cancer Liquid Biopsy Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.5. Breast Cancer Liquid Biopsy Market - Asia Pacific
    • 7.5.1. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.3. Breast Cancer Liquid Biopsy Market - China
      • 7.5.3.1. China: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.3.2. China: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.4. Breast Cancer Liquid Biopsy Market - India
      • 7.5.4.1. India: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.4.2. India: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.5. Breast Cancer Liquid Biopsy Market - Malaysia
      • 7.5.5.1. Malaysia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.6. Breast Cancer Liquid Biopsy Market - Japan
      • 7.5.6.1. Japan: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.7. Breast Cancer Liquid Biopsy Market - Indonesia
      • 7.5.7.1. Indonesia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.8. Breast Cancer Liquid Biopsy Market - South Korea
      • 7.5.8.1. South Korea: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.9. Breast Cancer Liquid Biopsy Market - Australia
      • 7.5.9.1. Australia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.10. Breast Cancer Liquid Biopsy Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.6. Breast Cancer Liquid Biopsy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.3. Breast Cancer Liquid Biopsy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.4. Breast Cancer Liquid Biopsy Market - UAE
      • 7.6.4.1. UAE: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.5. Breast Cancer Liquid Biopsy Market - Israel
      • 7.6.5.1. Israel: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.6. Breast Cancer Liquid Biopsy Market - South Africa
      • 7.6.6.1. South Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.7. Breast Cancer Liquid Biopsy Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.7. Breast Cancer Liquid Biopsy Market - Latin America
    • 7.7.1. Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.3. Breast Cancer Liquid Biopsy Market - Mexico
      • 7.7.3.1. Mexico: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.4. Breast Cancer Liquid Biopsy Market - Brazil
      • 7.7.4.1. Brazil: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.5. Breast Cancer Liquid Biopsy Market - Argentina
      • 7.7.5.1. Argentina: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.6. Breast Cancer Liquid Biopsy Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. The Menarini Group
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. NeoGenomics Laboratories
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. F. Hoffmann - La Roche Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Myriad Genetics, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Thermo Fisher Scientific, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. QIAGEN
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Biocept, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Sysmex Corporation
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Fluxion Biosciences, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Epic Sciences, Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development